Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-11-06
2007-11-06
Wehbe′, Anne M. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100
Reexamination Certificate
active
10933807
ABSTRACT:
Restenosis in a subject can be treated by administering to a tissue, e.g., a blood vessel, of the subject an agent that increases SERCA activity. For example, a stent that is coated with the agent can be introduced into a blood vessel.
REFERENCES:
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 5163952 (1992-11-01), Froix
patent: 5223263 (1993-06-01), Hostetler et al.
patent: 5252348 (1993-10-01), Schreier et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5304121 (1994-04-01), Sahatjian
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5674192 (1997-10-01), Sahatjian et al.
patent: 5766625 (1998-06-01), Schreier et al.
patent: 5858784 (1999-01-01), Debs et al.
patent: 5932299 (1999-08-01), Katoot
patent: 6024918 (2000-02-01), Hendriks et al.
patent: 6358556 (2002-03-01), Ding et al.
patent: 6379382 (2002-04-01), Yang
patent: 6387124 (2002-05-01), Buscemi et al.
patent: 6391052 (2002-05-01), Buirge et al.
patent: 6409716 (2002-06-01), Sahatjian et al.
patent: 6451594 (2002-09-01), Chien et al.
patent: 6506408 (2003-01-01), Palasis
patent: 6506437 (2003-01-01), Harish et al.
patent: 6527801 (2003-03-01), Dutta
patent: 6541116 (2003-04-01), Michal et al.
patent: 6545748 (2003-04-01), Trozera
patent: 6569194 (2003-05-01), Pelton
patent: 6572645 (2003-06-01), Leonhardt
patent: 6596699 (2003-07-01), Zamora et al.
patent: 6605110 (2003-08-01), Harrison
patent: 6605114 (2003-08-01), Yan et al.
patent: 6605274 (2003-08-01), Dillmann et al.
patent: 2002/0032167 (2002-03-01), Chien et al.
patent: 2002/0040010 (2002-04-01), Rosenzweig et al.
patent: 2002/0159978 (2002-10-01), Allen
patent: 2003/0073653 (2003-04-01), Bureau et al.
patent: 2003/0100889 (2003-05-01), Duverger et al.
patent: 2003/0166593 (2003-09-01), Chien et al.
patent: 2004/0121942 (2004-06-01), Chien et al.
patent: 2005/0095227 (2005-05-01), Rosenzweig et al.
patent: 1 319 419 (2003-06-01), None
patent: WO 96/13597 (1996-05-01), None
patent: WO 96/26742 (1996-09-01), None
patent: WO 96/33281 (1996-10-01), None
patent: WO 97/15679 (1997-05-01), None
patent: WO 99/04636 (1999-02-01), None
patent: WO 99/30696 (1999-06-01), None
patent: WO 02/087594 (2002-11-01), None
patent: WO 03/004088 (2003-01-01), None
patent: WO 2004/062618 (2004-07-01), None
Anger et al. Circulation 98: 2477-2486; 1998.
Thomas et al. Nature Rev./Genet. 4: 346-358; 2003.
Teucher et al. Molecular Cardiology, 110:3553-3559, 2004.
Periasamy Circulation Research 88:373-375; 2001.
O'Donnell Circulation Research. 88: 415-421; 2001.
Chen et al. Circulation 109:1898-1903; 2004.
Wilson et al. Adv. Drug Deliv. Rev. 46:205-209; 2001.
Anderson, “Human gene therapy,”Nature, 392(Suppl.):25-30 (Apr. 30, 1998).
Ardehali et al., “Direct gene transfer into donor hearts at the time of harvest,”J. Thorac. Cardiovasc. Surg., 109(4):716-720 (Apr. 1995).
Avril et al., “Defining the success of cardiac gene therapy: how can nuclear imaging contribute?”Eur. J. Nucl. Med. Mol. Imaging, 30(5):757-771 (May 2003).
Baudet et al., “Effects of Thapsigargin and Cyclopiazonic Acid on Twitch Force and Sarcoplasmic Reticulum Ca2+Content of Rabbit Ventricular Muscle,”Circ. Res., 73(5):813-819 (Nov. 1993).
Bernecker et al., “Gene Therapy for the Treatment of Heart Failure—Calcium Signaling,”Semin. Thorac. Cardiovasc. Surg., 15(3):268-276 (Jul. 2003).
Boussif et al., “A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine,”Proc. Natl. Acad. Sci. USA, 92:7297-7301 (Aug. 1995).
Chaudhri et al., “Contractile effects of adenovirally-mediated increases in SERCA2a activity: A comparison between adult rat and rabbit ventricular myocytes,”Mol. Cell. Biochem., 251:103-109 (2003).
Chaudhri et al., “Interaction between increased SERCA2a activity and β-adrenoceptor stimulation in adult rabbit myocytes,”Am. J. Physiol. Heart Circ. Physiol., 283:H2450-H2457 (Dec. 2002).
Chen et al., “Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo,”Proc. Natl. Acad. Sci. USA, 91:3054-3057 (Apr. 1994).
Chu et al., “Cardiomyocyte mechanics in transgenic mice expressing monomeric phospholamban,”Supplement to Circulation, 94(8):I-420, Abstract 2449 (Oct. 15, 1996).
Chu et al., “Compensatory Mechanisms Associated With the Hyperdynamic Function of Phospholamban-Deficient Mouse Hearts,”Circ. Res., 79(6):1064-1076 (Dec. 1996).
Chu et al., “Isolation of Sarcoplasmic Reticulum Fractions Referable to Longitudinal Tubules and Junctional Terminal Cisternae from Rabbit Skeletal Muscle,”Methods in Enzymology, 157:36-46 (1988).
Crystal, “Transfer of Genes to Humans: Early Lessons and Obstacles to Success,”Science, 270:404-410 (Oct. 20, 1995).
Curiel et al., “Gene Transfer to Respiratory Epithelial Cells via the Receptor-mediated Endocytosis Pathway,”Am. J. Respir. Cell Mol. Biol., 6(3):247-252 (Mar. 1992).
“CV gene therapy at Genzyme,”Scrip, No. 2196, p. 18 (Jan. 10, 1997).
Dalesandro et al., “Gene therapy for donor hearts: ex vivo liposome-mediated transfection,”J. Thorac. Cardiovasc. Surg., 111(2):416-422 (Feb. 1996).
Davia et al., “Functional alterations in adult rat myocytes after overexpression of phospholamban with use of adenovirus,”Physiol. Genomics, 1:41-50 (1999).
Davia et al., “SERCA2A Overexpression Decreases the Incidence of Aftercontrations in Adult Rabbit Ventricular Myocytes,”J. Mol. Cell. Cardiol., 33:1005-1015 (2001).
del Monte et al., “Efficient Viral Gene Transfer to Rodent Hearts In Vivo,”Methods Mol. Biol., 219:179-193 (2003).
del Monte et al., “Improvement in Survival and Cardiac Metabolism After Gene Transfer of Sarcoplasmic Reticulum Ca2+-ATPase in a Rat Model of Heart Failure,”Circulation, 104:1424-1429 (Sep. 18, 2001).
del Monte et al., “Overwhelming Evidence of the Beneficial Effects of SERCA Gene Transfer in Heart Failure,”Circ. Res., 88(11):E66-E67 (Jun. 8, 2001).
del Monte et al., “Restoration of Contractile Function in Isolated Cardiomyocytes From Failing Human Hearts by Gene Transfer of SERCA2a,”Circulation, 100:2308-2311 (Dec. 7, 1999).
del Monte et al., “Targeting calcium cycling proteins in heart failure through gene transfer,”J. Physiol., 546.1:49-61 (2003).
del Monte et al., “Targeting Phospholamban by Gene Transfer in Human Heart Failure,”Circulation, 105:904-907 (Feb. 26, 2002).
Deonarain, “Ligand-targeted receptor-mediated vactors for gene delivery,”Exp. Opin. Ther. Patents, 8(1):53-69 (1998).
Dong et al., “Identification of acis-Acting Sequence in the Human Plasminogen Activator Inhibitor Type-1 Gene That Mediates Transforming Growth Factor-β1 Responsivenessin Endothelium in Vivo,”J. Biol. Chem., 271(47):29969-29977 (Nov. 22, 1996).
Eastman et al., “A Concentrated and Stable Aerosol Formulation of Cationic Lipid:DNA Complexes Giving High-Level Gene Expression in Mouse Lung,”Hum. Gene Ther., 8:765-773 (Apr. 10, 1997).
Ebert et al., “A Monkey MLV-Rat Somatotropin Fusion Gene Produces Biologically Active Somatotropin in a Transgenic Pig,”Mol. Endocrinol., 2(3):277-283 (Mar. 1988).
Eizema et al., “Development of possibilities for gene therapy to improve the contractile properties of the failing heart,”J. Mol. Cell. Cardiol., 29(5):A125, Abstract Sa75 (1997).
Felgner et al., “Improved Cationic Lipid Formulations for in Vivo Gene Therapy,”Annals N.Y. Acad. Sci., 772:126-139 (1995).
Felgner et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,”Proc. Natl. Acad. Sci.USA, 84:7413-7417 (Nov. 1987).
Fisher et al., “Recombinant adeno-associated virus for muscle directed gene therapy,”Nature Medicine, 3(3):306-312 (Mar. 1997).
Genbank Accession
Del Monte Federica
Hajjar Roger J.
Lipskaia Larissa
Lompr Anne-Marie
Edwards Angell Palmer & & Dodge LLP
Lauro, Esq. Peter C.
Sajjadi Fereydoun G.
The General Hospital Corporation
Wehbe′ Anne M.
LandOfFree
Methods of treating restenosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating restenosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating restenosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3844368